JP2002507223A - 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルｌ−カルニチンをスタチンと組み合わせて含む医薬組成物 - Google Patents

脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルｌ−カルニチンをスタチンと組み合わせて含む医薬組成物

Info

Publication number
JP2002507223A
JP2002507223A JP50684499A JP50684499A JP2002507223A JP 2002507223 A JP2002507223 A JP 2002507223A JP 50684499 A JP50684499 A JP 50684499A JP 50684499 A JP50684499 A JP 50684499A JP 2002507223 A JP2002507223 A JP 2002507223A
Authority
JP
Japan
Prior art keywords
carnitine
alkanoyl
composition
statin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50684499A
Other languages
English (en)
Japanese (ja)
Inventor
カバッツァ，クラウディオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2002507223A publication Critical patent/JP2002507223A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP50684499A 1997-07-01 1998-06-18 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルｌ−カルニチンをスタチンと組み合わせて含む医薬組成物 Ceased JP2002507223A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97A000390 1997-02-24
IT97RM000390A IT1293067B1 (it) 1997-07-01 1997-07-01 Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
PCT/IT1998/000163 WO1999001126A1 (en) 1997-07-01 1998-06-18 Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Publications (1)

Publication Number Publication Date
JP2002507223A true JP2002507223A (ja) 2002-03-05

Family

ID=11405149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50684499A Ceased JP2002507223A (ja) 1997-07-01 1998-06-18 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルｌ−カルニチンをスタチンと組み合わせて含む医薬組成物

Country Status (10)

Country Link
US (2) US6180680B1 (cg-RX-API-DMAC10.html)
EP (2) EP1623708A3 (cg-RX-API-DMAC10.html)
JP (1) JP2002507223A (cg-RX-API-DMAC10.html)
KR (1) KR100539066B1 (cg-RX-API-DMAC10.html)
AU (1) AU726822B2 (cg-RX-API-DMAC10.html)
CA (1) CA2295748A1 (cg-RX-API-DMAC10.html)
IL (1) IL133492A (cg-RX-API-DMAC10.html)
IT (1) IT1293067B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ501844A (cg-RX-API-DMAC10.html)
WO (1) WO1999001126A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519333A (ja) * 2007-02-27 2010-06-03 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ２型糖尿病の処置に有用な組成物
JP2011513246A (ja) * 2008-02-29 2011-04-28 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 医薬組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
HUP0201597A3 (en) * 1999-06-08 2003-04-28 Sigma Tau Ind Farmaceutiche S Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
PT1064943E (pt) * 1999-06-30 2005-06-30 Sigma Tau Ind Farmaceuti Combinacao possuindo actividade antilipemica, substancialmente isenta dos efeitos toxicos ou efeitos secundarios provocados pelos farmacos antilipemicos
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITRM20040307A1 (it) 2004-06-23 2004-09-23 Sigma Tau Ind Farmaceuti Confezione per almeno due prodotti differenti da vendere e utilizzare insieme.
US8389574B2 (en) * 2007-03-21 2013-03-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
RU2329051C1 (ru) * 2007-04-02 2008-07-20 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Композиция, обладающая гиполипидемической и гепатопротекторной активностью
US11591288B2 (en) 2017-08-23 2023-02-28 Gavish-Galilee Bio Applications Ltd. Compositions and methods for treating atherosclerotic cardiovascular disease
CN120789042A (zh) * 2025-09-12 2025-10-17 广东海洋大学深圳研究院 Statine在制备抗结直肠肿瘤药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519333A (ja) * 2007-02-27 2010-06-03 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ２型糖尿病の処置に有用な組成物
JP2014040442A (ja) * 2007-02-27 2014-03-06 Sigma Tau Ind Farmaceut Riunite Spa ２型糖尿病の処置に有用な組成物
JP2011513246A (ja) * 2008-02-29 2011-04-28 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 医薬組成物

Also Published As

Publication number Publication date
WO1999001126A1 (en) 1999-01-14
NZ501844A (en) 2001-10-26
ITRM970390A1 (it) 1999-01-01
EP1623708A3 (en) 2006-02-15
KR20010014439A (ko) 2001-02-26
US20050026846A1 (en) 2005-02-03
EP0983066A1 (en) 2000-03-08
CA2295748A1 (en) 1999-01-14
IL133492A0 (en) 2001-04-30
EP1623708A2 (en) 2006-02-08
US6180680B1 (en) 2001-01-30
IL133492A (en) 2004-07-25
ITRM970390A0 (cg-RX-API-DMAC10.html) 1997-07-01
KR100539066B1 (ko) 2005-12-26
AU726822B2 (en) 2000-11-23
IT1293067B1 (it) 1999-02-11
AU7931098A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
JPS63203621A (ja) 高脂血症及び動脈硬化症の予防・治療薬
JP2002507223A (ja) 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルｌ−カルニチンをスタチンと組み合わせて含む医薬組成物
US20240408130A1 (en) Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
JP2001518481A (ja) 経口投与のためのセロトニン含有製剤及びその使用方法
US6245800B1 (en) Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
WO2005011642A1 (en) Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
KR100725263B1 (ko) ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
US20080287539A1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
US8003652B2 (en) Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
JP2002504934A (ja) ケタンセリンとｌ−カルニチン又はアルカノイルｌ−カルニチンを含むｃｒｐｓの治療のための組成物
JPH1129476A (ja) 麻薬依存抑制剤
EP1064943B1 (en) Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
JP2003535125A (ja) カルボキシアルキルエーテル−ａｃａｔ阻害剤の組合せ
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
JP2022540664A (ja) 石灰化減少に用いる経口ピロリン酸二ナトリウム
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090310